{
    "clinical_study": {
        "@rank": "114159", 
        "arm_group": [
            {
                "arm_group_label": "Phytosterol esters of omega-3", 
                "arm_group_type": "Experimental", 
                "description": "4 capsules/day for 12 weeks"
            }, 
            {
                "arm_group_label": "Omega-3 acid ethyl esters", 
                "arm_group_type": "Active Comparator", 
                "description": "4 capsules/day for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to determine the efficacy of phytosterol esters of omega-3\n      (Vayarol) versus Omega-3 acids ethyl esters in reducing triglyceride levels in\n      hypertriglyceridemia patients with fasting triglyceride levels \u2265 200 and < 500 mg/dL."
        }, 
        "brief_title": "The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Hypertriglyceridemia", 
        "condition_browse": {
            "mesh_term": "Hypertriglyceridemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, age > 18 years\n\n          2. Triglycerides \u2265 200 mg/dL and < 500 mg/dL\n\n          3. Ability to give written informed consent\n\n        Exclusion Criteria:\n\n          1. Female patient who are pregnant or breastfeeding or planning to become pregnant\n\n          2. Fasting plasma glucose (FPG) levels > 110 mg/dL\n\n          3. Type 2 diabetes mellitus that is poorly controlled (glycosylated hemoglobin [HbAlc ]\n             >8.0%\n\n          4. Patients who are under use of lipid altering drugs excluding use of Simvastatin,\n             Atorvastatin, and Rosovastatin for 6 weeks or more\n\n          5. Patients who are under use of products containing omega-3 fatty acids or other\n             dietary supplements with potential lipid altering effects\n\n          6. History of bariatric surgery or currently on weight loss drugs.\n\n          7. Uncontrolled hypertension (BP>140/90)\n\n          8. Subjects with secondary causes of hypertriglyceridemia: alcoholism, dysglobulinemia,\n             thyroid disease that is poorly controlled (TSH<0.35 or TSH>5.5)\n\n          9. Subjects with an abnormal level of liver enzymes (twice the normal level)\n\n         10. Suffered from ischemic event such as myocardial infarction, cerebrovascular accident\n             and angina pectoris in the last 6 months\n\n         11. Uncontrolled endocrine or metabolic disease known to influence serum lipids or\n             lipoproteins such as cushing syndrome\n\n         12. Gastrointestinal disease that may influence lipid metabolism such as celiac, crohn,\n             colitis or other malabsorption problem\n\n         13. Subjects who have had any malignancy. Subjects who have had basal cell carcinoma that\n             have been disease free for at least 3 years are eligible for the study.\n\n         14. Consumption of one fish serving (200 grams) or sea food x2 a week or more.\n\n         15. HIV infection by history\n\n         16. History of hypersensitivity or allergy to fish, fish oil or soy\n\n         17. BMI\u226535\n\n         18. Weight change > 3 kg during the run-in period\n\n         19. Any other reason that, in the opinion of the investigator, prevents the subject from\n             participating in the study or compromise the patient"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "206", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712867", 
            "org_study_id": "Vayarol_006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Omega-3 acid ethyl esters", 
                "description": "4 capsules/day for 12 weeks", 
                "intervention_name": "Omega-3 acid ethyl esters", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Phytosterol esters of omega-3", 
                "description": "4 capsules/day for 12 weeks", 
                "intervention_name": "Phytosterol esters of omega-3", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "contact": {
                "email": "Azuri_yo@mac.org.il", 
                "last_name": "Yossi Azuri, M.D", 
                "phone": "97235143738"
            }, 
            "contact_backup": {
                "email": "Daphna@enzymotec.com", 
                "last_name": "Daphna Zaaroor-Regev, PhD", 
                "phone": "972747177155"
            }, 
            "facility": {
                "address": {
                    "city": "Tel-Aviv", 
                    "country": "Israel"
                }, 
                "name": "Maccabi Healthcare Services"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels in Hypertriglyceridemia Patients: A Double-blind, Randomized, Noninferiority Trial", 
        "overall_official": {
            "affiliation": "Maccabi Healthcare Services, Israel", 
            "last_name": "Yossi Azuri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Research Ethics Committee"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Noninferiority of phytosterol esters of omega-3  in affecting plasma fasting triglyceride levels in comparison with Omega-3 acids ethyl esters.", 
            "measure": "fasting triglycerides levels", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712867"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Difference between phytosterol esters of omega-3  and Omega-3 acids ethyl esters treatment groups in other lipid and biomarker levels", 
            "measure": "Difference between phytosterol esters of omega-3  and Omega-3 acids ethyl esters treatment groups in other lipid and biomarker levels", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Enzymotec", 
        "sponsors": {
            "collaborator": {
                "agency": "Daewon Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Enzymotec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}